In the Phase 3 clinical trials of Zasocitinib, approximately 70% of patients achieved complete or near-complete clearance of skin symptoms at 16 weeks. Safety was consistent with previous trials with no new safety signals identified. Submission to the FDA in the United States is planned for fiscal 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4502-20260330-01.pdf","jir_short_summary":"In the Phase 3 clinical trials of Zasocitinib, approximately 70% of patients achieved complete or near-complete clearance of skin symptoms at 16 weeks. Safety was consistent with previous trials with no new safety signals identified. Submission to the FDA in the United States is planned for fiscal 2026.","jir_summary":"### Overview of Clinical Trial Results\nTakeda Pharmaceutical Company Limited demonstrated in the Phase 3 clinical trials (LATITUDE PsO 3001 and 3002) targeting patients with moderate to severe plaque psoriasis that approximately 70% of patients treated with Zasocitinib (TAK-279) achieved complete or near-complete clearance of skin symptoms (sPGA 0\/1) at 16 weeks. This represented a statistically significant improvement compared to the placebo group. The PASI 75 achievement rate also showed significant improvement, and the safety profile was consistent with the Phase 2b clinical trial without any new safety signals identified. These results suggest that Zasocitinib has the potential to provide rapid and sustained improvement in skin symptoms.\n\n### Future Outlook and Investor Briefing\nTakeda plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) and other regulatory authorities in fiscal 2026. An investor briefing on Phase 3 clinical trial data and market opportunities will be held via webcast on March 28 and 29, 2026. These clinical trial results are not expected to have a material impact on the full-year consolidated earnings forecast for the fiscal year ending March 2026 (fiscal 2025).","jir_financial_highlights":"Rate of complete or near-complete clearance of skin symptoms in Zasocitinib-treated patients: Approximately 70% (Unknown)\nPhysician\u2019s Global Assessment (sPGA) score 0\/1 achievement rate at 16 weeks: Zasocitinib group 71.4% and 69.2% (Significantly higher compared to placebo group at 10.7% and 12.6%)\nPASI 75 achievement rate at 16 weeks: Zasocitinib group 61.3% and 51.9% (Significantly improved compared to placebo group at 5.0% and 4.0%)\nIncidence of treatment-emergent adverse events (TEAE): Zasocitinib group 62.1% (Compared with placebo group 46.9% and apremilast group 50.5%)\nIncidence of serious TEAEs: Zasocitinib group 3.0% (Placebo group under 1%, apremilast group 1.5%)","jir_category":"","jir_hashtags":"#TakedaPharmaceuticalCompany, #NewDrugAnnouncement, #Zasocitinib, #PsoriasisTreatment, #ClinicalTrial","jir_key_figures":"sPGA 0\/1 achievement rate at 16 weeks in patients treated with Zasocitinib: Approximately 70%\nPASI 75 achievement rate at 16 weeks in patients treated with Zasocitinib: 61.3% and 51.9%\nIncidence of treatment-emergent adverse events (TEAE): Zasocitinib group 62.1%, placebo group 46.9%","jir_meta_title":"Takeda Pharmaceutical Achieves Approximately 70% Skin Symptom Clearance with Zasocitinib in Phase 3 Trial","jir_meta_description":"Takeda Pharmaceutical reports that approximately 70% of patients achieved complete or near-complete skin symptom clearance at 16 weeks in the Phase 3 clinical trial of Zasocitinib. Safety profile favorable with FDA submission planned for fiscal 2026.","jir_og_title":"Takeda Pharmaceutical Announces Phase 3 Clinical Trial Results of Zasocitinib","jir_og_description":"Zasocitinib rapidly and sustainably improves psoriasis symptoms, with approximately 70% of patients achieving symptom clearance at 16 weeks. Favorable safety profile with planned FDA submission.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-37562","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n